From a whole-genome map built on over a trillion lab-grown neurons, the partners pinpointed a novel neuro target in 15 months — the first payoff from a collaboration worth up to $12 billion.
The startup’s AI runs virtual versions of trials to predict patient responses and flag design flaws — aiming at the industry’s roughly 90% clinical-trial failure rate.
The Series B, led by General Atlantic, backs EXPD-101, a once-daily DPP1 inhibitor licensed from Fosun Pharma and now entering a global Phase 2 trial in COPD.
Kindred Companion Sciences edited a single gene to knock out Can f 1, the protein behind most dog allergies — and says two edited beagles are healthy at nearly two years old.
In flatworms, Stanford researchers found ‘ruptoblasts’ that self-destruct within seconds to destroy nearby bacteria — a defense mechanism never seen before.
The drugmaker added $1 billion to its savings target and raised its 2026 revenue outlook, even as COVID sales collapse and several cancer drugs slip.
University of Pennsylvania researchers found a gum made from lablab beans sharply reduced HPV in oral samples — an early, lab-only step toward preventing HPV-linked cancers.
A USC deep-learning model, trained on nearly 15,000 scans, shows which parts of the brain age fastest — and flags accelerated aging in areas hit early by Alzheimer’s.
Vertex raised guidance on $3.2B in quarterly CF sales, yet analysts are watching tiny Sionna Therapeutics, whose experimental drug could layer on top of Vertex’s Trikafta.
The KRAS G12C inhibitor earned the designation for previously treated advanced pancreatic cancer, one of oncology’s hardest targets, based on early-phase trial data.
Researchers explain how the brain “remembers” a higher body weight and defends it, helping explain why weight often returns after diets — or after stopping drugs like Wegovy.
The all-stock merger of equals unites Supernus’s brain-disorder portfolio with Indivior’s addiction treatments, forming a company with 11 marketed drugs.